四、问题与策略

更新于 2026年11月19日 版权声明
四、问题与策略

痴呆是重要的全球问题,由于不能治愈,减低痴呆风险、及时诊断和早期干预越来越多地受到人们的重视:①做好一级预防;②积极寻找其他可能的治疗途径,不要局限于目前已有的基础研究结果;③继续加强AD发病的分子生物学机制研究,研发新型AD药物;④利用我国中医药研究的传统优势嫁接和移植国际科技发展最新成果,以创新的方式提高中医药在AD方面的药物研究水平。

参考文献

[1]Karch CM,Goate AM.Alzheimer's disease risk genes and mechanisms of disease pathogenesis[J].Biol psychiatry,2015,77(1):43-51.

[2]Jelic V,Winblad B.Alzheimer disease:Donepezil and nursing home placement[mdash]benefits and costs[J].Nat Rev Neurol,2016,12(1):11-13.

[3]Jiang S,Li Y,Zhang C,et al.M1 muscarinic acetylcholine receptor in Alzheimer's disease[J].Neurosci Bulletin,2014,30(2):295-307.

[4]Oz M,Petroianu G,Lorke DE.α7-nicotinic acetylcholine receptors:new therapeutic avenues in Alzheimer's disease[J].Nicot Acetylchol Recept Technol,2016(2):149-169.

[5]Rosini M,Simoni E,Minarini A,et al.Multi-target design strategies in the context of Alzheimer's disease:acetylcholinesterase inhibition and NMDA receptor antagonism as the driving forces[J].Neurochem Res,2014,39(10):1914-1923.

[6]Schmidt R,Hofer E,Bouwman FH,et al.EFNS-ENS/EAN Guideline on concomitant use of cholinesterase inhibitors and memantine in moderate to severe Alzheimer's disease[J].Euro J Neurol,2015,22(6):889-898.

[7]Rissman RA,Mobley WC.Implications for treatment:GABAA receptors in aging,Down syndrome and Alzheimer's disease[J].J Neurochem,2011,117(4):613-622.

[8]Cummings JL,Morstorf T,Zhong K.Alzheimer's disease drug-developmentpipeline:few candidates,frequent failures[J].Alzheimer's Res Ther,2014,6(4):37.

[9]Wang X,Tucker NR,Rizki G,et al.Discovery and validation of subthreshold genome-wide association study loci using epigenomic signatures[J].Elife,2016,5:e10557.

[10]Marciani DJ.Alzheimer's disease vaccine development:A new strategy focusing on immune modulation[J].J Neuroimmunol,2015,287:54-63.

[11]Claxton A,Baker LD,Hanson A,et al.Long-acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia[J].J Alzheimer's Dis,2015,44(3):897-906.

[12]Wischik CM,Harrington CR,Storey JMD.Tau-aggregation inhibitor therapy for Alzheimer's disease[J].Biochem Pharmacol,2014,88(4):529-539.

[13]Wood WG,Li L,Müller WE,et al.Cholesterol as a causative factor in Alzheimer's disease:a debatable hypothesis[J].J Neurochem,2014,129(4):559-572.(https://www.daowen.com)

[14]Zissimopoulos JM,Barthold D,Brinton RD,et al.Sex and race differences in the association between statin use and the incidence of Alzheimer disease[J].JAMA Neurol,2017,74(2):225-232.

[15]Hu Y,Wang Z,Guo Q,et al.Is thyroid status associated with cognitive impairment in elderly patients in China?[J].BMC Endocr Dis,2016,16(1):11.

[16]Craft S,Baker LD,Montine TJ,et al.Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment:a pilot clinical trial[J].Arch Neurol,2012,69(1):29-38.

[17]Mikkola TS,Savolainen-Peltonen H,Tuomikoski P,et al.Lower death risk for vascular dementia than for alzheimer's disease with postmenopausal hormone therapy users[J].J Clin Endocrinol Metab,2016,102(3):870-877.

[18]Rafii MS,Baumann TL,Bakay RAE,et al.A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease[J].Alzheimers Dement,2014,10(5):571-581.

[19]Mangialasche F,Solomon A,Winblad B,et al.Alzheimer's disease:clinical trials and drug development[J].Lancet Neurol,2010,9(7):702-716.

[20]Salloway S,Sperling R,Fox NC,et al.Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease[J].New Engl J Med,2014,370(4):322-333.

[21]Panza F,Solfrizzi V,Imbimbo BP,et al.Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease[J].Exp Rev Neurotherap,2014,14(9):973-986.

[22]Doody RS,Thomas RG,Farlow M,et al.Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease[J].New Engl J Med,2014,370(4):311-321.

[23]Sevigny J,Chiao P,Bussière T,et al.The antibody aducanumab reduces Aβ plaques in Alzheimer's disease[J].Nature,2016,537(7618):50-56.

[24]Yan R,Vassar R.Targeting the β secretase BACE1 for Alzheimer's disease therapy[J].Lancet Neurol,2014,13(3):319-329.

[25]Small SA,Petsko GA.Retromer in Alzheimer disease,Parkinson disease and other neurological disorders[J].Nat Rev Neurosci,2015,16(3):126-132.

[26]Mecozzi VJ,Berman DE,Simoes S,et al.Pharmacological chaperones stabilize retromer to limit APP processing[J].Nat Chembiol,2014,10(6):443-449.

[27]Cummings JL,Zhong K,Kinney JW,et al.Double-blind,placebocontrolled,proof-of-concept trial of bexarotene in moderate Alzheimer's disease[J].Alzheimers Res Ther,2016,8(1):4.

(余年 林兴建)

✍AI写作